Endocrinology and Metabolism (May 2018)

Star-Shaped Intense Uptake of I on Whole Body Scans Can Reflect Good Therapeutic Effects of Low-Dose Radioactive Iodine Treatment of 1.1 GBq

  • Sung Hye Kong,
  • Jung Ah Lim,
  • Young Shin Song,
  • Shinje Moon,
  • Ye An Kim,
  • Min Joo Kim,
  • Sun Wook Cho,
  • Jae Hoon Moon,
  • Ka Hee Yi,
  • Do Joon Park,
  • Bo Youn Cho,
  • Young Joo Park

DOI
https://doi.org/10.3803/EnM.2018.33.2.228
Journal volume & issue
Vol. 33, no. 2
pp. 228 – 235

Abstract

Read online

BackgroundAfter initial radioactive iodine (RAI) treatment in differentiated thyroid cancer patients, we sometimes observe a star-shaped region of intense uptake of 131I on whole body scans (WBSs), called a ‘star artifact.’ We evaluated the clinical implications of star artifacts on the success rate of remnant ablation and long-term prognosis.MethodsTotal 636 patients who received 131I dose of 1.1 GBq for the initial RAI therapy and who did not show distant metastasis at the time of diagnosis were retrospectively evaluated. A negative second WBS was used for evaluating the ablation efficacy of the RAI therapy. Among them, 235 patients (36.9%) showed a star artifact on their first WBS.ResultsIn patients with first stimulated thyroglobulin (sTg) levels ≤2 ng/mL, patients with star artifacts had a higher rate of negative second WBS compared with those without star artifacts (77.8% vs. 63.9%, P=0.044), and showed significantly higher recurrence-free survival (P=0.043) during the median 8.0 years (range, 1.0 to 10.0) of follow-up. The 5- and 10-year recurrence rates (5YRR, 10YRR) were also significantly lower in patients with star artifacts compared with those without (0% vs. 4.9%, respectively, P=0.006 for 5YRR; 0% vs. 6.4%, respectively, P=0.005 for 10YRR). However, ablation success rate or recurrence-free survival was not different among patients whose first sTg levels >2 ng/mL regardless of star artifacts.ConclusionTherefore, star artifacts at initial RAI therapy imply a good ablation efficacy or a favorable long-term prognosis in patients with sTg levels ≤2 ng/mL.

Keywords